Program Schedule

249
Activity of Plazomicin Against Contemporary Isolates of Enterobacteriaceae from New York City

Session: Poster Abstract Session: Antimicrobial Resistance: Novel Agents and Approaches to Gram-negative Infections
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • IDSA-Plazomicin Poster-2014 -1- (1).pdf (133.9 kB)
  • Background: Plazomicin is a next generation aminoglycoside that is not affected by most commonly-encountered aminoglycoside modifying enzymes and is currently being studied in a global Phase 3 trial enrolling patients with bloodstream infections or nosocomial pneumonia due to carbapenem-resistant Enterobacteriaceae. The activity of this novel agent was tested against a contemporary collection of Enterobacteriaceae from New York City.

    Methods: Unique patient isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp. were gathered from 11 hospital microbiology laboratories from November 2013 through January 2014. Isolates underwent susceptibility testing by the agar dilution method according to CLSI guidelines. Cephalosporin-resistant isolates were screened for the presence of blaKPC.

    Results: A total of 2866 isolates of E. coli (two with blaKPC), 944 isolates of K. pneumoniae (125 with blaKPC), and 216 isolates of Enterobacter spp. (7 with blaKPC) were collected. Susceptibility results for gentamicin, amikacin, and plazomicin are shown in the table.

     

     

    MIC50

    MIC90

    Range

    Percent susceptible

     

    μg/ml

     

    E. coli (n=2866)

    Gentamicin

    1

    >8

    ≤0.25 - >8

    85%

    Amikacin

    2

    4

    ≤0.5 - >64

    99.5%

    Plazomicin

    1

    1

    0.12 - 4

     

    K. pneumoniae (n=944)

    Gentamicin

    0.5

    >8

    ≤0.25 - >8

    78%

    Amikacin

    2

    32

    ≤0.5 - >64

    88%

    Plazomicin

    0.5

    0.5

    0.12 - 32

     

    Enterobacter spp. (n=216)

    Gentamicin

    0.5

    2

    ≤0.25 - >8

    92%

    Amikacin

    2

    4

    ≤0.5 - 64

    97%

    Plazomicin

    0.5

    1

    0.25 - 4

     

    Among the 125 isolates of K. pneumoniae with blaKPC, the MIC50 and MIC90 values for plazomicin were 0.5 and 1 μg/ml, respectively.

    Conclusion: Plazomicin is an investigational aminoglycoside with broad-spectrum activity against common Enterobacteriaceae, including multidrug-resistant strains of K. pneumoniae. Further studies with this agent are warranted.

    Olawole Olafisoye, MD1, Marie Abdallah, MD1, Christopher Cortes, MD2, Carl Urban, PhD3, David Landman, MD4 and John Quale, MD4, (1)Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, NY, (2)Infectious Diseases, New York Hospital Queens, Flushing, NY, (3)Infectious Disease, New York Hospital Queens, Flushing, NY, (4)Medicine, SUNY Downstate Medical Center, Brooklyn, NY

    Disclosures:

    O. Olafisoye, None

    M. Abdallah, None

    C. Cortes, None

    C. Urban, Pfizer: Speaker's Bureau, Speaker honorarium
    Cubist: Speaker's Bureau, Speaker honorarium

    D. Landman, Tetraphase: Research Contractor, Research grant
    Achaogen: Research Contractor, Research grant

    J. Quale, Tetraphase: Research Contractor, Research grant
    Achaogen: Research Contractor, Research grant

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek